Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Health technology assessment bodies—independent organizations that evaluate new drugs for clinical effectiveness and cost-effectiveness—are raising significant questions about the true value of recently approved Alzheimer’s treatments. Rather than rubber-stamping new medications, these organizations are conducting rigorous analysis and often reaching sobering conclusions. The California Technology Assessment Forum (CTAF), for instance, recently voted unanimously that lecanemab, one of the newest FDA-approved Alzheimer’s drugs, provides only low long-term value for money, citing critical gaps in evidence about whether the drug’s benefits persist over time.
These assessments are reshaping how Alzheimer’s drugs reach patients globally. While the FDA in the United States focuses primarily on whether a drug works, health technology assessment bodies take a broader view: they examine whether the benefits justify the cost and whether better alternatives exist. Their findings increasingly conflict with optimistic marketing around Alzheimer’s treatments, forcing policymakers, insurers, and healthcare systems to make difficult choices about which drugs to cover and at what price.
Table of Contents
- How Do Health Technology Assessment Bodies Evaluate Alzheimer’s Drugs?
- The Lecanemab Controversy: What HTA Bodies Found
- FDA’s 2026 Decision Timeline and What’s Coming
- How European Health Systems Are Using HTA to Set Drug Prices
- The Durability Problem: Why Long-Term Data Matters
- What Recent Research from CTAD 2025 Reveals About Treatment Directions
- The Path Forward: Integration of HTA and FDA Processes
- Conclusion
How Do Health Technology Assessment Bodies Evaluate Alzheimer’s Drugs?
Health technology assessment (HTA) bodies are independent, science-based organizations that analyze new medications before they’re covered by insurance or public healthcare systems. In Europe and other countries with single-payer systems, these bodies hold enormous power—they essentially determine whether a drug will be available and affordable to patients. The process typically involves reviewing clinical trial data, comparing the new treatment to existing options, analyzing cost-effectiveness, and considering the burden of disease being treated. Unlike the FDA, which primarily asks “does this drug work?”, HTA bodies ask “is this drug worth what it costs?” The evaluation process is rigorous and can take months or years. Manufacturers submit extensive dossiers with clinical evidence, manufacturing information, and economic analyses.
Independent panels of clinicians, statisticians, health economists, and patient advocates review the data and debate the merits. For Alzheimer’s drugs specifically, HTA bodies must grapple with unique challenges: the disease progresses slowly, measuring cognitive benefit is difficult, and most trials last only 18 months, leaving questions about whether improvements last longer. The difference between FDA approval and HTA coverage became starkly apparent with lecanemab. The drug received FDA approval relatively quickly based on its ability to slow cognitive decline in early-stage Alzheimer’s. However, the CTAF panel concluded the drug provided “low long-term value,” expressing concerns about uncertain durability of benefit due to lack of long-term follow-up data—a limitation the approval process hadn’t addressed. This gap highlights why HTA scrutiny matters: manufacturers can win FDA approval based on short-term data, while HTA bodies force the harder question of whether those benefits last.
The Lecanemab Controversy: What HTA Bodies Found
Lecanemab, developed by Eisai and Biogen, entered a crowded field of Alzheimer’s treatments with considerable fanfare. It was the first anti-amyloid monoclonal antibody to show meaningful slowing of cognitive decline in early symptomatic disease, and the FDA granted it approval in July 2023. Yet when the California Technology Assessment Forum examined the drug, the panel reached a strikingly different conclusion than the FDA: lecanemab provides low long-term value for money. The CTAF raised multiple concerns, particularly about the absence of data beyond 18 months of treatment. The durability question is critical because Alzheimer’s is a long disease. A drug that slows decline for 18 months but shows no benefit thereafter might provide genuine value. But a drug that provides 18 months of slowing with unknown effects afterward is a gamble, especially at a high price point.
Lecanemab carries another limitation: it requires regular intravenous infusions and monitoring for amyloid-related imaging abnormalities (ARIA), a potential side effect involving brain inflammation or microhemorrhages. For some patients, the burden of treatment may outweigh modest cognitive benefits. The CTAF’s skepticism has reverberated through European health systems, complicating decisions about coverage and pricing. The European Alzheimer’s Disease Consortium highlighted an even more sobering reality: if the U.S. list price for lecanemab were applied across Europe, this single drug would consume approximately half the budget for all pharmaceuticals in Europe. This isn’t a criticism of one expensive drug in isolation—it illustrates the structural problem of pricing new Alzheimer’s treatments at U.S. levels. For European health systems already stretched thin, approving lecanemab at such a price would mean cutting funding for other medications, mental health services, or preventive care.
FDA’s 2026 Decision Timeline and What’s Coming
The pace of Alzheimer’s drug development has accelerated dramatically, and the FDA’s calendar for 2026 reflects this momentum. The agency is scheduled to rule on three dementia-related drugs this year, with the first decision expected by April 30, 2026, for Axsome Therapeutics’ AXS-05, which targets agitation in Alzheimer’s disease. This timeline matters because agitation is one of the most distressing behavioral symptoms for patients and caregivers, and a safe, effective treatment could genuinely improve quality of life. However, the FDA approval process will determine only whether AXS-05 works for agitation—not whether it’s worth the price or how it compares to behavioral interventions and existing medications. As these new drugs move toward approval, the gap between FDA decisions and HTA assessments will likely widen. The FDA may greenlight treatments that HTA bodies later reject or demand price reductions for.
This disconnect creates real problems for patients: a drug might be approved but unavailable or unaffordable in certain countries. U.S. patients with insurance coverage may have access, while European patients face rationing or denial based on HTA recommendations. For patients hoping to access the latest Alzheimer’s treatment, the regulatory landscape has become fragmented and unpredictable. The 2026 decisions will also be informed by recent research presented at the 2025 Clinical Trials on Alzheimer’s Disease (CTAD) conference, which documented new trial results and emerging treatment targets. As more data accumulates, both FDA reviewers and HTA bodies have richer information to work with. However, more data also reveals more complexity—new questions about subgroup responses, long-term safety, and comparative effectiveness that simple approval decisions cannot address.
How European Health Systems Are Using HTA to Set Drug Prices
European health systems have embraced HTA as a tool not just for coverage decisions but for negotiating prices. Rather than accepting manufacturers’ list prices, countries increasingly demand that prices reflect the drug’s actual clinical value. Health technology assessment bodies play the crucial role here: they conduct the analysis that governments use to push back against inflated pricing. If an HTA body concludes a drug provides modest benefit, negotiators can use that assessment to demand a lower price. The process varies by country. Some European nations, like the United Kingdom through the National Institute for Health and Care Excellence (NICE), publish explicit price-effectiveness thresholds—the amount they’re willing to pay for an additional year of healthy life. Others, like Germany, negotiate prices on a case-by-case basis.
For Alzheimer’s drugs specifically, European HTAs are increasingly skeptical of claims about “breakthrough” therapies when the underlying evidence is thin. This skepticism is justified: a drug that slows decline by a few months, requires monthly infusions, and carries risks of brain inflammation deserves hard scrutiny, not celebratory coverage. The European Alzheimer’s Disease Consortium’s finding about lecanemab consuming half of Europe’s pharmaceutical budget illustrates why this scrutiny matters. If approved at U.S. prices, lecanemab would devastate healthcare budgets. But if negotiated down to a price reflecting its modest clinical benefit and uncertain durability, it might fit within budgets while remaining accessible. The tension between access (getting drugs approved) and affordability (paying a reasonable price) has never been sharper in the Alzheimer’s field.
The Durability Problem: Why Long-Term Data Matters
One phrase appears repeatedly in HTA critiques of new Alzheimer’s drugs: “lack of long-term data.” This isn’t bureaucratic nitpicking—it reflects a fundamental problem with how Alzheimer’s drug trials are designed. Most trials run for 18 months, a timeframe chosen for practical reasons: shorter trials are faster and cheaper, and they’re sufficient to detect whether a drug slows cognitive decline compared to placebo. But 18 months tells you almost nothing about whether a patient treated for 5 or 10 years will see cumulative benefit. Consider lecanemab again. The trial showed that over 18 months, treated patients experienced slowing of cognitive decline compared to placebo—roughly a 35% slowing. Sounds meaningful, until you ask: what happens in months 19 through 36? Does the benefit continue? Does it plateau? Do treated patients eventually catch up to placebo patients? If a patient stops the drug after 18 months, do they experience accelerated decline? The trial simply doesn’t answer these questions.
HTA bodies insist on asking them because patients and health systems need to know whether the benefit is durable—whether paying for years of treatment produces years of benefit or merely delays decline. This uncertainty has real consequences. A patient with early-stage Alzheimer’s might be told the drug slows decline by 35% based on 18-month trial data. They might enroll expecting years of benefit. But if the drug’s effect wanes over time, or if it merely delays cognitive decline without changing the ultimate trajectory, the patient’s expectations will be disappointed. HTA bodies are essentially insisting that manufacturers collect longer-term data and be honest about durability before claiming transformative benefit. The absence of this data is a warning sign: it suggests either that long-term benefit is uncertain or that manufacturers haven’t invested in finding out.
What Recent Research from CTAD 2025 Reveals About Treatment Directions
The 2025 Clinical Trials on Alzheimer’s Disease conference provided critical updates on where Alzheimer’s treatment research is heading. Researchers presented new trial results and discussed emerging treatment targets beyond amyloid, including tau pathology, neuroinflammation, and vascular contributions to cognitive decline. These presentations reveal a field in ferment—there’s growing recognition that amyloid-targeting drugs, while potentially useful, aren’t a panacea. CTAD 2025 highlighted both successes and limitations of current approaches.
Researchers demonstrated that combination treatments (attacking multiple pathological processes simultaneously) may offer better outcomes than single-agent drugs. They also presented data on patient subgroups who respond better or worse to amyloid-targeting therapies, suggesting that one-size-fits-all treatment approaches may be outdated. For HTA bodies evaluating future drugs, this research underscores the need for better biomarker-based patient selection and more sophisticated outcome measures. A drug that works in a carefully selected patient subgroup may not be as valuable to a broader population—and HTAs will increasingly demand evidence of who benefits and who doesn’t.
The Path Forward: Integration of HTA and FDA Processes
The tension between FDA approval and HTA assessment will likely become a defining feature of Alzheimer’s drug development going forward. Manufacturers increasingly need to think beyond U.S. approval and consider how their drugs will be evaluated by European and other HTA bodies. This might incentivize longer trials, more rigorous cost-effectiveness analysis, and more realistic claims about benefit.
Conversely, HTA bodies are learning from the rapid pace of Alzheimer’s drug approvals and may need to adapt their processes to avoid indefinitely delaying access to potentially beneficial treatments. A more integrated approach might involve HTA input earlier in drug development, allowing manufacturers to design trials that will satisfy both FDA and HTA requirements. Some regulatory systems are experimenting with adaptive pathways and conditional approvals tied to post-marketing data collection—essentially approving drugs with the requirement that manufacturers prove long-term durability. For Alzheimer’s disease, this could mean approving drugs like lecanemab with the condition that treatment must be shown to provide durable benefit over 5-10 years, with coverage contingent on real-world evidence. Such approaches balance access (letting patients get the drug sooner) with accountability (requiring proof that it works long-term).
Conclusion
Health technology assessment bodies are fundamentally challenging how we evaluate Alzheimer’s treatments. Rather than celebrating drugs that show short-term slowing of cognitive decline, they’re asking harder questions: Does the benefit last? Is it worth the cost? Could the money be better spent elsewhere? These questions reflect the reality that resources are finite and that patients deserve honest information about what new treatments can and cannot do. The findings from bodies like the California Technology Assessment Forum—that lecanemab provides low long-term value—should prompt patients, families, and clinicians to approach new Alzheimer’s drugs with informed skepticism, not reflexive enthusiasm.
As the FDA prepares to rule on multiple dementia drugs in 2026 and European health systems negotiate prices, the role of HTA bodies will only grow more important. For patients and families considering Alzheimer’s treatment, the key takeaway is simple: approval by the FDA doesn’t mean a drug is definitively beneficial or affordable. Talk with your neurologist about what a drug is actually proven to do, how long the benefit lasts, and whether the treatment burden fits your values and goals. Look beyond marketing claims and regulatory announcements to the underlying evidence—and recognize that HTA bodies’ skepticism often reflects legitimate scientific uncertainty, not obstruction.
You Might Also Like
- Regulatory Technology Solutions Streamline Alzheimer’s Drug Submissions
- Technology Assistance Programs Help Alzheimer’s Patients Stay Connected
- Smart Home Technology Supports Independent Living for Alzheimer’s Patients
For more, see National Institute on Aging.
